318 related articles for article (PubMed ID: 36140466)
1. Pediatric Diffuse Midline Gliomas: An Unfinished Puzzle.
Di Ruscio V; Del Baldo G; Fabozzi F; Vinci M; Cacchione A; de Billy E; Megaro G; Carai A; Mastronuzzi A
Diagnostics (Basel); 2022 Aug; 12(9):. PubMed ID: 36140466
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy approaches for the treatment of diffuse midline gliomas.
Bernstock JD; Hoffman SE; Kappel AD; Valdes PA; Essayed W; Klinger NV; Kang KD; Totsch SK; Olsen HE; Schlappi CW; Filipski K; Gessler FA; Baird L; Filbin MG; Hashizume R; Becher OJ; Friedman GK
Oncoimmunology; 2022; 11(1):2124058. PubMed ID: 36185807
[TBL] [Abstract][Full Text] [Related]
3. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
Pachocki CJ; Hol EM
J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
[TBL] [Abstract][Full Text] [Related]
4. Pediatric diffuse midline glioma H3K27- altered: A complex clinical and biological landscape behind a neatly defined tumor type.
Vallero SG; Bertero L; Morana G; Sciortino P; Bertin D; Mussano A; Ricci FS; Peretta P; Fagioli F
Front Oncol; 2022; 12():1082062. PubMed ID: 36727064
[TBL] [Abstract][Full Text] [Related]
5. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology, Diagnostic Strategies, and Therapeutic Advances in Diffuse Midline Glioma.
Miguel Llordes G; Medina Pérez VM; Curto Simón B; Castells-Yus I; Vázquez Sufuentes S; Schuhmacher AJ
J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629304
[No Abstract] [Full Text] [Related]
7. Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.
Noon A; Galban S
Neoplasia; 2023 Jun; 40():100899. PubMed ID: 37030112
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
[TBL] [Abstract][Full Text] [Related]
9. HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma.
Wang SS; Davenport AJ; Iliopoulos M; Hughes-Parry HE; Watson KA; Arcucci V; Mulazzani M; Eisenstat DD; Hansford JR; Cross RS; Jenkins MR
Neurooncol Adv; 2023; 5(1):vdad024. PubMed ID: 37152812
[TBL] [Abstract][Full Text] [Related]
10. Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma.
Price G; Bouras A; Hambardzumyan D; Hadjipanayis CG
EBioMedicine; 2021 Jul; 69():103453. PubMed ID: 34157482
[TBL] [Abstract][Full Text] [Related]
11. Extra-neural metastases in pediatric diffuse midline gliomas, H3 K27-altered: presentation of two cases and literature review.
De Martino L; Picariello S; Russo C; Errico ME; Spennato P; Papa MR; Normanno N; Scimone G; Colafati GS; Cacchione A; Mastronuzzi A; Massimino M; Cinalli G; Quaglietta L
Front Mol Neurosci; 2023; 16():1152430. PubMed ID: 37547920
[TBL] [Abstract][Full Text] [Related]
12. [Diffuse midline glioma].
Saito R
No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
[TBL] [Abstract][Full Text] [Related]
13. Advances in Treatment of Diffuse Midline Gliomas.
Cacciotti C; Wright KD
Curr Neurol Neurosci Rep; 2023 Dec; 23(12):849-856. PubMed ID: 37921944
[TBL] [Abstract][Full Text] [Related]
14. Past, present and future of Focused Ultrasound as an adjunct or complement to DIPG/DMG therapy: A consensus of the 2021 FUSF DIPG meeting.
Parekh K; LeBlang S; Nazarian J; Mueller S; Zacharoulis S; Hynynen K; Powlovich L
Neoplasia; 2023 Mar; 37():100876. PubMed ID: 36709715
[TBL] [Abstract][Full Text] [Related]
15. Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review.
Hashii Y; Oka Y; Kagawa N; Hashimoto N; Saitou H; Fukuya S; Kanegae M; Ikejima S; Oji Y; Ozono K; Tsuboi A; Sugiyama H
Front Oncol; 2020; 10():1188. PubMed ID: 32793489
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic programming of pediatric high-grade glioma: Pushing beyond proof of concept to clinical benefit.
Groves A; Cooney TM
Front Cell Dev Biol; 2022; 10():1089898. PubMed ID: 36589742
[TBL] [Abstract][Full Text] [Related]
17. Predicting outcome in childhood diffuse midline gliomas using magnetic resonance imaging based texture analysis.
Szychot E; Youssef A; Ganeshan B; Endozo R; Hyare H; Gains J; Mankad K; Shankar A
J Neuroradiol; 2021 Jun; 48(4):243-247. PubMed ID: 32184119
[TBL] [Abstract][Full Text] [Related]
18. Clinical Features and Prognosis of Diffuse Midline Glioma: A Series of 24 Cases.
Jang SW; Song SW; Kim YH; Cho YH; Hong SH; Kim JH; Ra YS; Chong S
Brain Tumor Res Treat; 2022 Oct; 10(4):255-264. PubMed ID: 36347640
[TBL] [Abstract][Full Text] [Related]
19. Pediatric diffuse midline glioma: Understanding the mechanisms and assessing the next generation of personalized therapeutics.
Jovanovich N; Habib A; Head J; Hameed F; Agnihotri S; Zinn PO
Neurooncol Adv; 2023; 5(1):vdad040. PubMed ID: 37152806
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathological characteristics of H3K27-altered diffuse midline glioma and evaluation of NTRK as its therapeutic target].
Duan ZJ; Feng J; Yao K; Hu ZJ; Ma Z; Xiang L; Zhang XF; Qi XL
Zhonghua Bing Li Xue Za Zhi; 2022 Nov; 51(11):1115-1122. PubMed ID: 36323540
[No Abstract] [Full Text] [Related]
[Next] [New Search]